Laboratorio Reig Jofre

Laboratorio Reig Jofre FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Laboratorio Reig Jofre (RJF.MC) as of Nov 22, 2026 is 101.69 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 67.45 % — a change of 50.76% (higher).

FCF Conversion

101.69 %

YoY

50.76%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Laboratorio Reig Jofre is 2024 101.69 % . FCF Conversion Rate (FCF/EBITDA) of Laboratorio Reig Jofre was 2023 67.45 % . It decreases by 50.76% higher compared to the previous year.

The Laboratorio Reig Jofre FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
35.45 EUR
Jan 1, 2018
-68.11 EUR
Jan 1, 2019
-393.89 EUR
Jan 1, 2020
115.55 EUR
Jan 1, 2021
-103.40 EUR
Jan 1, 2022
58.57 EUR
Jan 1, 2023
67.45 EUR
Jan 1, 2024
101.69 EUR
The Laboratorio Reig Jofre FCF Conversion history
YEARFCF ConversionYoY
101.69 %+50.76%
67.45 %+15.17%
58.57 %-156.64%
-103.40 %-189.48%
115.55 %-129.34%
-393.89 %+478.27%
-68.11 %-292.16%
35.45 %-119.81%
-178.91 %-753.37%
27.38 %-105.86%
-467.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Laboratorio Reig Jofre Stock analysis

What does Laboratorio Reig Jofre do? Laboratorio Reig Jofre SA is a leading company in the pharmaceutical industry, specializing in the development, manufacturing, and marketing of drugs. The company was founded in 1929 by the Reig Jofre brothers in Barcelona, Spain. It has since become an international company with a wide portfolio of products and a high level of innovation and quality. The business model of Laboratorio Reig Jofre SA is based on implementing research and innovation in the field of pharmacy. The company has its own R&D department, which collaborates closely with major scientific organizations and universities in Spain to understand and apply the latest developments and innovations in the industry. Laboratorio Reig Jofre SA has three main divisions - human pharmaceuticals, veterinary medicine, and chemical products used in various industries such as cosmetics and food. The human pharmaceutical division includes a variety of products, including prescription drugs, over-the-counter products, and generics, with a focus on therapy areas such as oncology, antibiotics, gynecology, and central nervous system disorders. The veterinary medicine division provides a wide range of vaccines and medications for animal health. The third division of chemical products includes various products such as emulsifiers, preservatives, and natural dyes that can be used in different industries. Some of the most well-known products of Laboratorio Reig Jofre SA include the antibiotic Nitrofurantoin, the analgesic Algiasdin, the hormonal preparation Ovusitol, and the vaccine against Bluetongue in animals. The company has also carried out several successful acquisitions to expand its portfolio and strengthen its international presence. The acquisition of Derivados Quimicos SA (Derma SA) introduced Laboratorio Reig Jofre SA to the skincare sector and strengthened its presence in Latin America. The acquisition of Bioiberica SA introduced the company to the field of bioactive molecules and chondroprotectants. Laboratorio Reig Jofre SA is a company that places quality and innovation at the heart of its activities. The company has a strong corporate culture based on respect, transparency, integrity, and commitment. It has also shown a strong commitment to sustainability and social responsibility, with initiatives such as supporting projects to improve the health of women and children in Africa and implementing environmentally friendly practices in production. Overall, Laboratorio Reig Jofre SA is a leading company in the pharmaceutical industry, capable of offering a wide range of products through research, innovation, and quality. With its diverse portfolio of products and its commitment to sustainability and social responsibility, the company is well-equipped to continue playing a leading role in the industry in the future. Laboratorio Reig Jofre is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Laboratorio Reig Jofre stock

FCF Conversion Rate (FCF/EBITDA) of Laboratorio Reig Jofre is 101.69 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of Laboratorio Reig Jofre changed from 67.45 % to 101.69 %, representing a 50.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Laboratorio Reig Jofre since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Laboratorio Reig Jofre with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Laboratorio Reig Jofre

All Key Metrics — Laboratorio Reig Jofre